Format

Send to

Choose Destination
Bioorg Med Chem Lett. 1998 Feb 3;8(3):301-6.

Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile.

Author information

1
DuPont Merck Pharmaceutical Company, Wilmington, DE 19880-0500, USA.

Abstract

The potent boropeptide thrombin inhibitor DuP 714 caused side effects in laboratory animals that appear to be related to its ability to inhibit complement factor I, thereby activating the complement cascade. Using X-ray crystal structure information, we have designed compounds that have greater selectivity for thrombin over factor I and that have reduced tendency to produce these side effects.

PMID:
9871674
DOI:
10.1016/s0960-894x(98)00013-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center